Participants in this research study have advanced or metastatic kidney cancer and will receive either subitinib or cabozantinib. The purpose of this research study is to find out what effects these drugs have on advanced or metastatic kidney cancer. Sunitinib has been approved by the U.S. Food and Drug Administration (FDA) and cabozantinib is an investigational drug (which means it has not been approved by the FDA). Both medications target special proteins that are on the surface of the kidney cancer cell and both drugs are taken by mouth.
Approximately 15 people will take part in this study at the University of Iowa and approximately 150 nationwide.